Blackstone Invests $250M in Anagram Therapeutics for Cystic Fibrosis Therapy

A $250 million investment is helping advance therapy for a condition that affects patients with cystic fibrosis, pancreatic cancer, and related disorders.

Ropes & Gray represented Blackstone Life Sciences in its investment in Anagram Therapeutics, a clinical-stage private biopharmaceutical company focused on exocrine pancreatic insufficiency.

The Ropes & Gray team was led by life sciences transactions partner Rajarshi Banerjee and IP transactions partner Melissa Rones and included Michael D. Beauvais, Deidre Johnson, Derek Yee, Michael Spera, and Ryan Murphey.

https://www.ropesgray.com/en/news-and-events/news/2026/05/blackstone-life-sciences-invests-in-anagram-therapeutics-to-advance-therapy-for-pancreatic

#biotech investment #cystic fibrosis therapy #pancreatic cancer #life sciences #clinical trials